Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis
Recruiting now · Not applicable · Has a placebo group
Conditions studied: Cystic Fibrosis in Children
In brief
The aim of the present study is to investigate the effect of probiotic supplementation on GI related quality of life, through a randomised placebo-controlled clinical trial. Moreover, the invetigators wish to study CF microbiota and intestinal inflammation in the setting of probiotic supplementation and newly started treatment with a highly effective CF-specific treatment, elexacaftor-tezacaftor-ivacaftor (ETI). The proposed project has the potential to increase QoL and decrease GI morbidity in children with CF. If successful, the results of this study can contribute to alter the care of CF patients by including supplementation of probiotics in routine CF care. Morever, the study can provide much needed insights to GI microbiota and inflammation in pediatric CF patients.
Key facts
- Study ID
- NCT06284577
- Run by
- Oslo University Hospital
- People needed
- 40
- Starts
- 2024-01-02
- Expected to finish
- 2027-07-01
- Last updated by the study team
- 2024-06-13
Who can join
Age: 2 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Oslo University Hospital — Oslo, Norway (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.